samedan logo
 
 
 
spacer
home > ebr > spring 2003 > the development of parp inhibitors to treat cancer and other diseases
PUBLICATIONS
European Biopharmaceutical Review

The Development of PARP Inhibitors to Treat Cancer and Other Diseases

There is currently much debate in the pharmaceutical industry regarding the future of cancer treatment. Only time will tell if research into anti-angiogenesis, vaccines, monoclonal antibodies and myriad signalling pathways, among other therapeutic strategies, will provide returns on investment and significantly improve the treatment of cancer. At the same time, the knowledge gained from current cancer research and targeted drug discovery programmes must be viewed in light of the opportunities that it may offer for treating other important human diseases. It is important to realise that vast libraries of compounds are generated during the course of the cancer drug discovery process and many of these may have uses in disease areas that do not strategically fit with the goals and focus of the developer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Stephen P Jackson, Deputy Chairman of the Wellcome Trust/Cancer Research UK Institute of Cancer and Developmental Biology, and Founder of KuDOS Pharmaceuticals Ltd

Professor Stephen P Jackson is Deputy Chairman of the Wellcome Trust/Cancer Research UK Institute of Cancer and Developmental Biology, and is the Frederick James Quick Professor of Biology at the University of Cambridge. He founded KuDOS Pharmaceuticals Ltd together with Cancer Research Technology and the University of Cambridge in 1997.

In 2002, Professor Jackson was awarded the Anthony Dipple Carcinogenesis Young Investigators' Award for his contributions in the field of molecular oncology, and in 1997 he received both the Tenovus Medal and the Biochemical Society Colworth Medal. He has also been elected a member of the European Molecular Biology Organization. He holds a PhD in molecular biology from the University of Edinburgh.

spacer
Professor Stephen P Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Qatar Airways Becomes Largest Passenger and Cargo Airline Globally Despite the Illegal Blockade and COVID-19 Crisis

Airline’s resolve to continue operating and growing over the last three years in the face of the illegal blockade has enabled the airline to succeed during the COVID-19 crisis The Best Airline in the World has built strong levels of trust with passengers and governments around the world for continuing to operate to take people home and its leadership on safety measures Hamad International Airport, The Best Airport in the Middle East, leads the way with strong levels of customer service while implementing the latest technologies to optimise passenger and employee safety
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement